Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab182759-100μg
|
100μg |
10
|
$69.90
|
|
|
Ab182759-1mg
|
1mg |
4
|
$319.90
|
|
|
Ab182759-5mg
|
5mg |
1
|
$659.90
|
|
|
Ab182759-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,049.90
|
|
| Product Name | Litifilimab (anti-CLEC4C) - Primary antibody, specific to CLEC4C, Human IgG1, INHIBITOR of C-type lectin domain family 4 member C inhibitor |
|---|---|
| Synonyms | BDCA-2 antibody | BDCA2 antibody | Blood dendritic cell antigen 2 antibody | Blood dendritic cell antigen 2 protein antibody | C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 11 antibody | C-type (calcium dependent, |
| Specifications & Purity | RUO, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | CLEC4C |
| Conjugation | Unconjugated |
| Grade | Animal Free, RUO |
| Action Type | INHIBITOR |
| Mechanism of action | INHIBITOR of C-type lectin domain family 4 member C inhibitor |
| Product Description |
Litifilimab (anti-CLEC4C) is a humanized IgG1-κ antibody targeting to C-type lectin domain family 4 member C (CLEC4C). Litifilimab (anti-CLEC4C) can be used for cutaneous lupus erythematosus (CLE) study. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 28.0 kDa (Light Chain) & 50.7 kDa (Heavy Chain), under reducing conditions; 204.4 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 2407378-48-5 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Litifilimab (anti-CLEC4C) (Ab182759) - ELISA
Immobilized BDCA2-ECD-his at 2.0 μg/mL can bind Litifilimab (anti-CLEC4C) (Ab182759) with the EC
₅₀
of 19.73 ng/mL.
Litifilimab (anti-CLEC4C) (Ab182759) - SEC
The purity of Litifilimab (anti-CLEC4C) (Ab182759) is more than 95% verified by HPLC.
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Jun 28, 2024 | Ab182759 | |
| Certificate of Analysis | Jun 28, 2024 | Ab182759 | |
| Certificate of Analysis | Jun 28, 2024 | Ab182759 |